This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Selected Positron Emission Tomography Technologies for Evaluation of Alzheimer Disease

Amyloid beta imaging with positron emission tomography (PET) to predict conversion to Alzheimer disease is considered investigational.
Amyloid beta imaging with PET as an adjunct to clinical diagnosis in patients with dementia is considered investigational.

Amyloid beta imaging with PET to select patients with mild cognitive impairment or mild dementia due to Alzheimer disease for amyloid beta targeting plaque-therapy is considered investigational.

Amyloid beta imaging with PET to evaluate patients with mild cognitive impairment or mild dementia due to Alzheimer disease for continuation of amyloid beta plaque-targeting therapy is considered investigational.

PET Imaging with fluorine 18 fluorodeoxyglucose (FDG-PET) as an adjunct to clinical diagnosis in patients with dementia is considered investigational.

All other uses of amyloid beta imaging with PET are considered investigational.

787-277-6653 787-474-6326